214 related articles for article (PubMed ID: 20215136)
1. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
[No Abstract] [Full Text] [Related]
2. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
3. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
5. [mTOR and non-small cell lung cancer].
Wang L; Xu S; Yue W
Zhongguo Fei Ai Za Zhi; 2010 Jan; 13(1):69-72. PubMed ID: 20672708
[No Abstract] [Full Text] [Related]
6. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
7. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus.
Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
[TBL] [Abstract][Full Text] [Related]
9. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Subbiah V; Trent JC; Kurzrock R
J Clin Oncol; 2010 Aug; 28(24):e415. PubMed ID: 20567010
[No Abstract] [Full Text] [Related]
10. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors in polycystic kidney disease.
Watnick T; Germino GG
N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
[No Abstract] [Full Text] [Related]
12. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
Benson C; Vitfell-Rasmussen J; Maruzzo M; Fisher C; Tunariu N; Mitchell S; Al-Muderis O; Thway K; Larkin J; Judson I
Anticancer Res; 2014 Jul; 34(7):3663-8. PubMed ID: 24982384
[TBL] [Abstract][Full Text] [Related]
13. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
14. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
15. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
16. Malignant variant of sclerosing perivascular epithelioid cell tumor arising in the adnexa.
Ramaiah S; Ganesan R; Mangham DC; McNally O; Klys HS; Hirschowitz L
Int J Gynecol Pathol; 2009 Nov; 28(6):589-93. PubMed ID: 19851212
[TBL] [Abstract][Full Text] [Related]
17. Perivascular epithelioid cell tumor (PEComa) of the uterus with aggressive behavior at presentation.
Liu JL; Lin YM; Lin MC; Yeh KT; Hsu JC; Chin CJ
Hematol Oncol Stem Cell Ther; 2009; 2(3):426-30. PubMed ID: 20139058
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus for metastatic desmoplastic small round cell tumor.
Thijs AM; van der Graaf WT; van Herpen CM
Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).
Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U
World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.
Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D
World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]